Public Summary

Summary for ARTG Entry:	256772	BLACKMORES LYPRINOL
ARTG entry for	Medicine Listed	
Sponsor	Blackmores Ltd	
Postal Address	217-221 Governor Road, Braeside, VIC, 3195 Australia	
ARTG Start Date	21/08/2015	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . BLACKMORES LYPRINOL

Product Type Single Medicine Product **Effective Date** 30/09/2025

Permitted Indications

Maintain/support general health and wellbeing

Anti-inflammatory/relieve inflammation

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must only refer to mild joint symptoms.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

'Contains mollusc' or 'Contains mollusc products'.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	

Active Ingredients	
Green lipped mussel oil	**50 mg**
Other Ingredients (Excipients)	
d-alpha-tocopherol	
Gelatin	
glycerol	
Olive Oil	
purified water	

Public Summary